USA

The partnership expands the use of ALT B4, a proprietary recombinant human hyaluronidase developed through Alteogen’s Hybrozyme platform.

The acquisition adds rare endocrine diseases as a new growth area alongside Vertex’s existing focus on cystic fibrosis, hematology, acute pain and renal disease.

AusperBio will use a significant portion of the proceeds to advance AHB 137, an antisense oligonucleotide therapy for CHB, through its Phase III registrational programme and toward potential commercialisation.

Kowa is seeking approval based on results from the pivotal Phase III Mont Blanc and Denali trials.

Photonova Spectra uses the company’s Deep Silicon detector technology to produce high-definition images while providing spectral and spatial imaging capabilities.

Cushing’s syndrome of endogenous origin occurs when the body produces excessive amounts of cortisol and other steroid hormones.

Amyl Therapeutics will expand its laboratory facilities at the LegiaPark life sciences campus in Liège, Belgium, to accommodate its growing research programme.

The acquisition will give Lilly access to Merida’s technology for developing biologics that selectively eliminate disease-causing autoantibodies.

Under the agreement, Teva would acquire worldwide rights to Igalmi (dexmedetomidine) sublingual film, a prescription medicine, as well as BXCL501, an investigational therapy.

The decision follows positive results from the Phase III VALOR trial (NCT05437263), which showed that Lisraya improved several measures of dermatomyositis disease activity.